Skip to content
OpenCapital
Get started

Cyclerion Therapeutics CYCN Q4 2025 Annual earnings

Reported March 30, 2026 · After market close

Revenue$100.0KIn lineDiluted EPS-$0.19Beat by $0.19
Revenue estimate$100.0K
EPS estimate-$0.38

Next report

Aug 4, 2026 (In 3 weeks)
Revenue estimate$1.5M
EPS estimate-$7.10

Versus estimates

Revenue

Q4 2025$100.0KIn line
Q1 2024$100.0KIn lineQ3 2025$875.0KQ2 2025$93.0KQ1 2025$81.0K

Diluted EPS

Q1 2026-$0.76Beat by $16.44
Q4 2025-$0.19Beat by $0.19
Q1 2024-$0.38In lineQ3 2025-$0.30Q2 2025-$0.11Q1 2025-$0.56

Ask the moment Cyclerion Therapeutics reports.

Connect your AI and ask the moment the filing drops. It reads the release, surfaces what management said, and gives you its own read.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

When did Cyclerion Therapeutics report Q4 2025 earnings?
Cyclerion Therapeutics (CYCN) reported Q4 2025 earnings on March 30, 2026 after market close.
What were Cyclerion Therapeutics's Q4 2025 revenue and EPS?
Cyclerion Therapeutics reported revenue of $100.0K and diluted EPS of $-0.19 for Q4 2025.
Did Cyclerion Therapeutics beat estimates in Q4 2025?
Revenue beat the consensus estimate of $100.0K by -. EPS beat the consensus estimate of $-0.38 by $0.19.
How did Cyclerion Therapeutics's Q4 2025 results compare year-over-year?
Compared to the same quarter a year prior, revenue declined 94.5% from $1.8M a year earlier.
Where can I find Cyclerion Therapeutics's Q4 2025 SEC filings?
You can read the 8-K earnings release (0001193125-26-137909) and the 10-K periodic report (0001193125-26-132193) directly on SEC EDGAR. The filing index links above go to sec.gov.